Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6146MR)

This product GTTS-WQ6146MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6146MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12507MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NOE-102
GTTS-WQ11261MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI4736
GTTS-WQ2636MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 592
GTTS-WQ9637MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ7904MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GSK-249320
GTTS-WQ9733MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JR-141
GTTS-WQ7708MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GEXMab73
GTTS-WQ11693MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MHAB5553A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW